Focal 18F-NaF PET Prostate Activity in the Setting of Prostate Adenocarcinoma

Clin Nucl Med. 2020 Jul;45(7):e334-e335. doi: 10.1097/RLU.0000000000003094.

Abstract

A 72-year-old man with a family history of prostate cancer and initial diagnosis of favorable intermediate risk prostate cancer via biopsy in 2017 elected for active surveillance. Two years later, he underwent prostate biopsy showing intermediate-risk cT1c Nx Mx lesion with Gleason score 3 + 4 = 7 (5 core positive). Transrectal ultrasound showed a prostate volume 28 mL, and the prostate-specific antigen was 8.1. Patient elected to proceed with combination radiation therapy and androgen deprivation therapy.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnostic imaging*
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology
  • Aged
  • Androgen Antagonists / therapeutic use
  • Biopsy
  • Fluorine Radioisotopes*
  • Humans
  • Male
  • Neoplasm Grading
  • Positron-Emission Tomography
  • Prostate-Specific Antigen / metabolism
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology
  • Sodium Fluoride*
  • Ultrasonography

Substances

  • Androgen Antagonists
  • Fluorine Radioisotopes
  • Sodium Fluoride
  • Prostate-Specific Antigen
  • Fluorine-18